Assessment of Overall and Specific Cancer Risks in Patients With Hidradenitis Suppurativa
- PMID: 32459291
- PMCID: PMC7254443
- DOI: 10.1001/jamadermatol.2020.1422
Assessment of Overall and Specific Cancer Risks in Patients With Hidradenitis Suppurativa
Abstract
Importance: Large population-based studies investigating the risks of overall and specific cancers among patients with hidradenitis suppurativa (HS) are limited.
Objective: To assess the overall and specific cancer risks in patients with HS compared with the risks in patients without HS in the Republic of Korea.
Design, setting, and participants: A nationwide population-based cohort study, using the Korean Health Insurance Review and Assessment Service database was conducted over a 2-year period from January 1, 2007, to December 31, 2008. Individuals in the control group who were never diagnosed with HS or cancer during the washout period were randomly extracted and matched by age, sex, index year, and insurance type at a case-control ratio of 1:8, and patients with newly diagnosed HS between January 1, 2009, and December 31, 2017, were included. Follow-up data on incident cancer from January 1, 2009, to December 31, 2018, were included.
Main outcomes and measures: The overall and specific cancer incidence rates were calculated per 100 000 person-years in patients with HS and in the matched control cohort. The risk for cancers was assessed by multivariable Cox regression models in patients with HS compared with the matched control cohort.
Results: In total, 22 468 patients with HS and 179 734 matched controls were included in the study. The mean (SD) age was 33.63 (17.61) years and 63.7% of the participants in both groups were male. The adjusted hazard ratio (aHR) of overall cancer in patients with HS was 1.28 (95% CI, 1.15-1.42). Patients with HS had significantly higher risk for Hodgkin lymphoma (aHR, 5.08; 95% CI, 1.21-21.36), oral cavity and pharyngeal cancer (aHR, 3.10; 95% CI, 1.60-6.02), central nervous system cancer (aHR, 2.40; 95% CI, 1.22-4.70), nonmelanoma skin cancer (HR, 2.06; 95% CI, 1.12-3.79), prostate cancer (aHR, 2.05; 95% CI, 1.30-3.24), and colorectal cancer (aHR, 1.45; 95% CI, 1.09-1.93).
Conclusions and relevance: In this study, HS appeared to be associated with a significantly increased risk of overall cancer as well as several specific cancers.
Conflict of interest statement
Figures
Similar articles
-
Smoking Cessation and Risk of Hidradenitis Suppurativa Development.JAMA Dermatol. 2024 Oct 1;160(10):1056-1065. doi: 10.1001/jamadermatol.2024.2613. JAMA Dermatol. 2024. PMID: 39167402
-
Incidence of anxiety disorder in adults with hidradenitis suppurativa.Br J Dermatol. 2024 Aug 14;191(3):351-356. doi: 10.1093/bjd/ljae139. Br J Dermatol. 2024. PMID: 38564268
-
Association of Birth Weight, Childhood Body Mass Index, and Height With Risk of Hidradenitis Suppurativa.JAMA Dermatol. 2020 Jul 1;156(7):746-753. doi: 10.1001/jamadermatol.2020.1047. JAMA Dermatol. 2020. PMID: 32347905 Free PMC article.
-
Hidradenitis suppurativa in the pediatric population.J Am Acad Dermatol. 2015 Nov;73(5 Suppl 1):S36-41. doi: 10.1016/j.jaad.2015.07.051. J Am Acad Dermatol. 2015. PMID: 26470613 Review.
-
Race-Specific Prevalence of Hidradenitis Suppurativa.J Cutan Med Surg. 2021 Mar-Apr;25(2):177-187. doi: 10.1177/1203475420972348. Epub 2020 Nov 11. J Cutan Med Surg. 2021. PMID: 33174482 Review.
Cited by
-
Hidradenitis Suppurativa and Maternal and Offspring Outcomes.JAMA Dermatol. 2024 Oct 16:e243584. doi: 10.1001/jamadermatol.2024.3584. Online ahead of print. JAMA Dermatol. 2024. PMID: 39412794
-
Hidradenocarcinoma in a Crohn's patient on ustekinumab: A case report.SAGE Open Med Case Rep. 2024 Jul 26;12:2050313X241254732. doi: 10.1177/2050313X241254732. eCollection 2024. SAGE Open Med Case Rep. 2024. PMID: 39071199 Free PMC article.
-
A state-of-the-art systematic review of cancer in hidradenitis suppurativa.Ann Med. 2024 Dec;56(1):2382372. doi: 10.1080/07853890.2024.2382372. Epub 2024 Jul 24. Ann Med. 2024. PMID: 39046819 Free PMC article.
-
Integrated bioinformatics combined with machine learning to analyze shared biomarkers and pathways in psoriasis and cervical squamous cell carcinoma.Front Immunol. 2024 May 28;15:1351908. doi: 10.3389/fimmu.2024.1351908. eCollection 2024. Front Immunol. 2024. PMID: 38863714 Free PMC article.
-
Deregulated Long Non-Coding RNAs (lncRNA) as Promising Biomarkers in Hidradenitis Suppurativa.J Clin Med. 2024 May 20;13(10):3016. doi: 10.3390/jcm13103016. J Clin Med. 2024. PMID: 38792557 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
